Wang Xue, Bishop Courtney, O'Callaghan James, Gayhoor Ali, Albani Justin, Theriault Wendy, Chappell Michael, Golay Xavier, Wang Danny, Becerra Lino
Invicro, Boston, MA, USA.
GE Healthcare.
Drug Discov Today. 2023 Apr;28(4):103506. doi: 10.1016/j.drudis.2023.103506. Epub 2023 Jan 20.
Neurodegenerative mechanisms affect the brain through a variety of processes that are reflected as changes in brain structure and physiology. Although some biomarkers for these changes are well established, others are at different stages of development for use in clinical trials. One of the most challenging biomarkers to harmonize for clinical trials is cerebral blood flow (CBF). There are several magnetic resonance imaging (MRI) methods for quantifying CBF without the use of contrast agents, in particular arterial spin labeling (ASL) perfusion MRI, which has been increasingly applied in clinical trials. In this review, we present ASL MRI techniques, including strategies for implementation across multiple imaging centers, levels of confidence in assessing disease progression and treatment effects, and details of image analysis.
神经退行性机制通过多种过程影响大脑，这些过程表现为大脑结构和生理的变化。尽管这些变化的一些生物标志物已得到充分确立，但其他一些仍处于临床试验应用的不同开发阶段。在临床试验中，最难统一的生物标志物之一是脑血流量（CBF）。有几种磁共振成像（MRI）方法可在不使用造影剂的情况下定量CBF，特别是动脉自旋标记（ASL）灌注MRI，它已越来越多地应用于临床试验。在本综述中，我们介绍了ASL MRI技术，包括在多个成像中心实施的策略、评估疾病进展和治疗效果的置信水平以及图像分析的细节。
